Results 221 to 230 of about 3,006,553 (325)
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source
H3F3B p.K27I-mutant diffuse midline glioma is a distinct subtype of H3K27-altered diffuse midline glioma. [PDF]
Cheng L+14 more
europepmc +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou+5 more
wiley +1 more source
"In silico analysis of human TLR3 missense single nucleotide polymorphisms and their potential association with cancer". [PDF]
Agarwal M+5 more
europepmc +1 more source
INTERACTIONS BETWEEN SOME RECESSIVE LETHAL AND VISIBLE MUTATIONS OF THE FOURTH CHROMOSOME OF DROSOPHILA MELANOGASTER [PDF]
Elizabeth Ambellan, Timothy Prout
openalex +1 more source
Single‐cell transcriptomics of prostate cancer patient‐derived xenografts reveals distinct features of neuroendocrine (NE) subtypes. Tumours with focal NE differentiation (NED) share transcriptional programmes with adenocarcinoma, differing from large and small cell neuroendocrine prostate cancer (NEPC). Our work defines the molecular landscape of NEPC,
Rosalia Quezada Urban+12 more
wiley +1 more source
To The Editor a Novel Mutation in MALT1 Deficiency. [PDF]
Kose H.
europepmc +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts+8 more
wiley +1 more source
Precise correction of G6PD Viangchan mutation in iPSCs by prime editing strategy. [PDF]
Netsawang C+3 more
europepmc +1 more source
Loss‐of‐function mutations in the scaffold subunit of protein phosphatase 2A (PP2A), PPP2R1A, sensitize ovarian clear cell carcinoma to immune checkpoint blockade (ICB) by enhancing the interferon gamma response and promoting antitumor immune cell infiltration.
Matheus Henrique Dias, René Bernards
wiley +1 more source